NCT07022496 Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals
| NCT ID | NCT07022496 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Ain Shams University |
| Condition | Migraine |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2023-04-26 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 120 participants in total. It began in 2023-04-26 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Caffeine extracted from green tea to abort acute attack of Migraine
Eligibility Criteria
Inclusion Criteria: Patients suffering from migraine with aura, migraine without aura, episodic, and chronic migraine according to ICHD-3 diagnosis will be legible for the study. Exclusion Criteria: Patients who have history of any cardiac dysrhythmia, hypertension, ischemic heart disease, active peptic ulcer disease, inflammatory bowel disease, obsessive compulsive disorder, pregnancy, breast-feeding, renal failure, hepatic failure, sleep disorder, mental retardation, and history of substance abuse that prevent them from cooperating with us during the study Patients who had headache due to: Cluster headache, trigeminal neuralgia, glossopharyngeal neuralgia, headache secondary to trauma, cranial disorder, vascular disorder, infection, or mass lesion, will also be excluded
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07022496 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07022496 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07022496 currently recruiting?
Yes, NCT07022496 is actively recruiting participants. Contact the research team at nourhanelguindy@gmail.com for enrollment information.
Where is the NCT07022496 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07022496 clinical trial?
NCT07022496 is sponsored by Ain Shams University. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.